Investigation of treatment volume versus circulating blood volume during Rheocarna treatment.

Autor: Hoshikawa Y; Medical Engineering Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan., Ohkubo A; Medical Engineering Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan., Sakurasawa T; Medical Engineering Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan., Usui M; Medical Engineering Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan., Deushi M; Medical Engineering Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan., Yamamoto H; Medical Engineering Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan., Naito S; Department of Nephrology, Tokyo Medical and Dental University, Tokyo, Japan.
Jazyk: angličtina
Zdroj: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy [Ther Apher Dial] 2024 Aug; Vol. 28 (4), pp. 505-510. Date of Electronic Publication: 2024 Mar 07.
DOI: 10.1111/1744-9987.14117
Abstrakt: Introduction: Rheocarna's therapeutic effect is associated with fibrinogen (Fib) and low-density lipoprotein cholesterol (LDL-C) adsorptive removal. This study aimed to retrospectively investigate the association between treatment volume (TV) and circulating blood volume (CBV) and the Fib removal rate (Fib-RR) and LDL-C-RR.
Methods: CBV and TV/CBV, cut-off value (CO value), and area under the receiver operating characteristic (ROC) curve (AUC) were calculated. The Fib-RR and LDL-C-RR at the midterm and end of treatment were compared. The groups were further categorized into three groups with TV/CBV lower than or higher than the CO value at the midterm and end (midterm/end; Group L: lower than/lower than CO; Group L/H: lower than/higher than CO; Group H: higher than/higher than CO), and the Fib-RR and LDL-RR of each group at the midterm and end were compared.
Results: ROC analysis revealed a TV of 1.480 times the BV as CO value, which showed a maximum Youden index predicting a Fib-RR of 20% (AUC: 0.828). Among the three groups, Group L and Group L/H demonstrated significantly higher Fib-RR and LDL-C-RR at the end of the study than in the midterm, while Group H exhibited no difference.
Conclusion: The results reveal that a treatment volume of 1.5 times the circulating blood volume is a sufficient solute removal capacity in the Rheocarna-enabled cases.
(© 2024 International Society for Apheresis and Japanese Society for Apheresis.)
Databáze: MEDLINE
Externí odkaz: